AstraZeneca's IMFINZI and IMJUDO combination shows progression benefit in liver cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
April 2, 2026 7:00 AM EDTIMFINZI plus IMJUDO combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
IMFINZI plus IMJUDO combined with lenvatinib and transarterial chemoembolization (TACE) showed trend toward improved overall survival
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the EMERALD-3 Phase III trial showed AstraZenecas IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transarterial chemoembolization (TACE) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint... More
